AGIOS PHARMACEUTICALS INC

AGIONASDAQ

🏆 #1682 by market capEarnings Oct 29US Equity

$32.69▲ $0.10 (+0.31%)

Market closed · at close

1h—

24h▲ 0.3%

7d▲ 3.1%

14d▼ 6.6%

30d▼ 19.5%

1y▼ 7.4%

🏦Market Cap

$1.94B

Small Cap

📈Revenue Growth (YoY)

+140.6%

High Growth

📊Gross Margin

92.0%

High

💵FCF Margin

—

⚖️P/S Ratio

19.6x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $32.48 – $32.87
52-Week Range: $22.24 – $46.00
Volume: $3.50B
Avg Volume: $3.08B
Shares Outstanding: 59.5M
Next Earnings: Sep 23, 2026

Fundamentals Snapshot

Annual Revenue: $54M
Last Q Revenue: $45M
P/E Ratio: —
P/S Ratio: 19.6x
EPS (TTM): $-7.01
Dividend Yield: —

Why Investors Own AGIO

✓High-growth profile — revenue up +49.4% YoY with expanding US Equity exposure.
✓Healthy economics — 34% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$54M▲ +43.6% YoY

Gross Margin (TTM)

34.0%▲ +3.1% YoY

Operating Income (TTM)

$11M▲ +43.6% YoY

Free Cash Flow (TTM)

$6M▲ +43.6% YoY

About AGIOS PHARMACEUTICALS INC

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

🦦